Clinical Trials Logo

X-Linked Retinitis Pigmentosa clinical trials

View clinical trials related to X-Linked Retinitis Pigmentosa.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05926583 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

Start date: September 12, 2023
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).

NCT ID: NCT05874310 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

Start date: February 1, 2023
Phase: Early Phase 1
Study type: Interventional

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

NCT ID: NCT04868916 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa

Start date: July 26, 2021
Phase:
Study type: Observational

The purpose of the study is to identify a cohort of Japanese participants with X-linked retinitis pigmentosa (XLRP) associated with pathogenic variants in the retinitis pigmentosa GTPase regulator (RPGR) gene and to investigate their associated phenotype.

NCT ID: NCT04850118 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Start date: March 14, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.